Loading...

Flowr

OTCPK:FLWP.F
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FLWP.F
OTCPK
CA$609M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

The Flowr Corporation cultivates and produces medicinal cannabis in Canada. The last earnings update was 111 days ago. More info.


Add to Portfolio Compare Print
  • Flowr has significant price volatility in the past 3 months.
FLWP.F Share Price and Events
7 Day Returns
-7.9%
OTCPK:FLWP.F
0.7%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-
OTCPK:FLWP.F
8.6%
US Pharmaceuticals
1.9%
US Market
FLWP.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Flowr (FLWP.F) -7.9% 66.7% 88.2% - - -
US Pharmaceuticals 0.7% 0.5% 5.1% 8.6% 18.6% 20.5%
US Market 2.4% 1.7% 11.9% 1.9% 38.2% 42.4%
1 Year Return vs Industry and Market
  • No trading data on FLWP.F.
  • No trading data on FLWP.F.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Flowr undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Flowr to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our intrinsic value calculation method has changed recently, learn more here.

Below are the data sources, inputs and calculation used to determine the intrinsic value for Flowr.

OTCPK:FLWP.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:FLWP.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.682 (1 + (1- 26.5%) (0%))
0.787
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for OTCPK:FLWP.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Flowr is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:FLWP.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 -14.00 Analyst x1 -13.02
2020 0.00 Analyst x1 0.00
2021 34.00 Analyst x1 27.37
2022 17.00 Analyst x1 12.73
2023 53.00 Analyst x1 36.92
2024 55.35 Est @ 4.43% 35.87
2025 57.52 Est @ 3.92% 34.67
2026 59.57 Est @ 3.56% 33.40
2027 61.54 Est @ 3.31% 32.10
2028 63.47 Est @ 3.14% 30.80
Present value of next 10 years cash flows CA$230.85
OTCPK:FLWP.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CA$63.47 × (1 + 2.73%) ÷ (7.5% – 2.73%)
CA$1,367.54
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$1,367.54 ÷ (1 + 7.5%)10
CA$663.65
OTCPK:FLWP.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$230.85 + CA$663.65
CA$894.49
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$894.49 / 86.72
CA$7.71
OTCPK:FLWP.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:FLWP.F represents 0.74786x of TSXV:FLWR
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.74786x
Value per Share
(Listing Adjusted, USD)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 10.31 x 0.74786
$7.71
Value per share (USD) From above. $7.71
Current discount Discount to share price of $5.25
= -1 x ($5.25 - $7.71) / $7.71
31.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Flowr is available for.
Intrinsic value
32%
Share price is $5.25 vs Future cash flow value of $7.71
Current Discount Checks
For Flowr to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Flowr's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Flowr's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Flowr's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Flowr's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:FLWP.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.15
TSXV:FLWR Share Price ** TSXV (2019-03-18) in CAD CA$7.02
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.34x
United States of America Market PE Ratio Median Figure of 3,055 Publicly-Listed Companies 17.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Flowr.

OTCPK:FLWP.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:FLWR Share Price ÷ EPS (both in CAD)

= 7.02 ÷ -0.15

-46.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Flowr is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Flowr is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Flowr's expected growth come at a high price?
Raw Data
OTCPK:FLWP.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -46.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
101.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 1.51x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Flowr, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Flowr's assets?
Raw Data
OTCPK:FLWP.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$0.72
TSXV:FLWR Share Price * TSXV (2019-03-18) in CAD CA$7.02
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 178 Publicly-Listed Pharmaceuticals Companies 3.41x
United States of America Market PB Ratio Median Figure of 5,152 Publicly-Listed Companies 1.87x
OTCPK:FLWP.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:FLWR Share Price ÷ Book Value per Share (both in CAD)

= 7.02 ÷ 0.72

9.74x

* Primary Listing of Flowr.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Flowr is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Flowr's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Flowr has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Flowr expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
101.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Flowr expected to grow at an attractive rate?
  • Flowr's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Flowr's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Flowr's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:FLWP.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:FLWP.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 101.5%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:FLWP.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:FLWP.F Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 205 1
2022-12-31
2021-12-31 147 41 38 1
2020-12-31 94 9 7 2
2019-12-31 24 2 1 2
2018-12-31 2 -13 -14 2
OTCPK:FLWP.F Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 -7 -11
2018-06-30 -5 -6
2018-03-31 -4 -4
2017-12-31 -3 -2
2016-12-31 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Flowr's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Flowr is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:FLWP.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Flowr Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:FLWP.F Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.54 0.54 0.54 1.00
2020-12-31 0.10 0.10 0.10 1.00
2019-12-31 0.01 0.01 0.01 1.00
2018-12-31 -0.19 -0.19 -0.19 1.00
OTCPK:FLWP.F Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.15
2018-06-30 -0.12
2018-03-31 -0.09
2017-12-31 -0.05
2016-12-31 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Flowr will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Flowr's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Flowr has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Flowr performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Flowr's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Flowr does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Flowr's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Flowr's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Flowr's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Flowr Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:FLWP.F Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -11.33 10.11 0.37
2018-06-30 -6.16 6.61 0.19
2018-03-31 -4.03 4.75 0.09
2017-12-31 -1.91 2.89
2016-12-31 -1.32 2.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Flowr has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Flowr has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Flowr improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Flowr's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Flowr has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Flowr's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Flowr's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Flowr is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Flowr has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Flowr's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Flowr has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Flowr Company Filings, last reported 5 months ago.

OTCPK:FLWP.F Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 62.19 0.00 39.66
2018-06-30 26.89 0.00 9.51
2018-03-31 19.55 0.00 7.75
2017-12-31 19.55 0.00 7.75
2016-12-31 3.95 0.00 1.12
  • Flowr has no debt.
  • Flowr has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Flowr has sufficient cash runway for 1.7 years based on current free cash flow.
  • Flowr has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 93.4% each year.
X
Financial health checks
We assess Flowr's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Flowr has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Flowr's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Flowr dividends.
If you bought $2,000 of Flowr shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Flowr's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Flowr's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:FLWP.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2004 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:FLWP.F Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Flowr has not reported any payouts.
  • Unable to verify if Flowr's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Flowr's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Flowr has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Flowr's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Flowr afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Flowr has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Flowr's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vinay Tolia
COMPENSATION CA$0
AGE 39
TENURE AS CEO 0.3 years
CEO Bio

Mr. Vinay Tolia serves as Co-Chief Executive Officer of The Flowr Corporation since November 9, 2018. Mr. Tolia has served as the Chief Executive Officer at The Flowr Corporation since August 15, 2018 and its Executive Director since October 26, 2018. Mr. Tolia was the Founder at Bengal Capital Trading LLC and served as its Managing Partner. He served as Senior Analyst and Trader of Midtown Long and Short Equity Fund at Pergament Advisors, LLC. His primary responsibilities include investment research and idea generation. Prior to joining the firm, Mr. Tolia spent two years as an Investment Banking Analyst with CIBC World Markets and Peter J. Solomon Company, LP. His experiences also include trading equity derivatives at Peak6 Capital Management in Chicago and serving as a Research Analyst with UBS Warburg in Stamford. Mr. Tolia is a graduate of the University of Michigan with a B.A. degree in Economics and a B.S.E. degree in Industrial Engineering with an emphasis in Financial Engineering.

CEO Compensation
  • Insufficient data for Vinay to compare compensation growth.
  • Vinay's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Flowr management team in years:

0.3
Average Tenure
46.5
Average Age
  • The average tenure for the Flowr management team is less than 2 years, this suggests a new team.
Management Team

Steve Klein

TITLE
Co-Founder
AGE
54

Vinay Tolia

TITLE
Co-CEO & Executive Director
AGE
39
TENURE
0.3 yrs

Tom Flow

TITLE
Co-Founder
COMPENSATION
CA$201K
AGE
41
TENURE
0.3 yrs

Alex Dann

TITLE
Chief Financial Officer
COMPENSATION
CA$33K
AGE
52
TENURE
1.2 yrs

Lyle Oberg

TITLE
Chief Policy & Medical Officer and Executive Director
COMPENSATION
CA$80K
AGE
58

Lance Emanuel

TITLE
President
TENURE
0.3 yrs

Ernest Broome

TITLE
Chief Research & Innovation Officer

Francesco Tallarico

TITLE
General Counsel & Corporate Secretary
AGE
35
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Flowr board of directors in years:

0.5
Average Tenure
54
Average Age
  • The average tenure for the Flowr board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Klein

TITLE
Co-Founder
AGE
54

Vinay Tolia

TITLE
Co-CEO & Executive Director
AGE
39
TENURE
0.4 yrs

Tom Flow

TITLE
Co-Founder
COMPENSATION
CA$201K
AGE
41
TENURE
0.5 yrs

Lyle Oberg

TITLE
Chief Policy & Medical Officer and Executive Director
COMPENSATION
CA$80K
AGE
58
TENURE
0.5 yrs

Rishi Shah

TITLE
Independent Director
AGE
31
TENURE
0.5 yrs

Karen Basian

TITLE
Independent Director
AGE
55
TENURE
0.3 yrs

Maurice Levesque

TITLE
Independent Director
AGE
59
TENURE
0.3 yrs

David Miller

TITLE
Director
AGE
54
TENURE
0.5 yrs

J. André De Teixeira

TITLE
Independent Director
AGE
65
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Oct 18 Buy David Towill Individual 26. Sep 18 26. Sep 18 7,600 $5.59 $42,451
22. Oct 18 Sell David Ralston Individual 15. Oct 18 19. Oct 18 -71,000 $4.07 $-277,646
18. Oct 18 Sell Lyle Oberg Individual 15. Oct 18 15. Oct 18 -10,000 $4.05 $-40,491
14. Oct 18 Sell David Ralston Individual 09. Oct 18 12. Oct 18 -4,100 $4.24 $-16,299
X
Management checks
We assess Flowr's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Flowr has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

The Flowr Corporation cultivates and produces medicinal cannabis in Canada. The company is based in Lake Country, Canada.

Details
Name: The Flowr Corporation
FLWP.F
Exchange: OTCPK
Founded:
CA$456,188,266
86,718,660
Website: http://www.flowr.ca
Address: The Flowr Corporation
100 Allstate Parkway,
Suite 201,
Markham,
Ontario, L3R 6H3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV FLWR Common Shares TSX Venture Exchange CA CAD 26. Sep 2018
OTCPK FLWP.F Common Shares Pink Sheets LLC US USD 26. Sep 2018
Number of employees
Current staff
Staff numbers
77
Flowr employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/19 00:53
End of day share price update: 2019/03/18 00:00
Last estimates confirmation: 2019/02/25
Last earnings filing: 2018/11/28
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.